
SunRISe-1: Examining Combination Therapy for HR NMIBC
1) A medical urologist discusses the rationale and design of the SunRISe-1 phase 2 trial, which evaluates the combination of intravesical TAR-200 and systemic cetrelimab, as well as the TAR-200 and cetrelimab monotherapy arms, in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC), focusing on key efficacy and safety endpoints.
Episodes in this series

Discuss the rationale and design of the SunRISe-1 phase 2 trial evaluating the combination of intravesical TAR-200 and systemic cetrelimab,as well as the TAR-200 and cetrelimab monotherapy arms, in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC). What are the key efficacy and safety endpoints?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.